<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114272">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01857167</url>
  </required_header>
  <id_info>
    <org_study_id>DUOLI2013011</org_study_id>
    <nct_id>NCT01857167</nct_id>
  </id_info>
  <brief_title>Effect of Omega-3 Fatty Acids on Insulin Sensitivity in Chinese Type 2 Diabetic Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <authority>China: Ethics Committee of the College of Biosystem Engineering &amp; Food Science, Zhejiang University</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to examine the change of fasting insulin, glucose, insulin sensitivity and
      related traits in response to the six month treatment of omega-3 fatty acids, including fish
      oil and flaxseed oil, in Chinese type 2 diabetic patients. Corn oil, rich in omega-6 fatty
      acids, will be selected as a controlled oil. The investigators hypothesize that omega-3
      fatty acids could improve insulin sensitivity and glucose metabolism in Chinese type 2
      diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The insulin resistance will be estimated by a homeostatic model assessment model of insulin
      resistance (HOMA-IR)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>insulin resistance</measure>
    <time_frame>180 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Fish Oil Supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive fish oil capsules, at a dose of 4g/day. Each 1g capsule will contain 220mg of EPA and 170mg of DHA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flaxseed Oil Supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive flaxseed oil capsule, at a dose of 4g/day. Each 1g capsule will contain 550mg of ALA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Supplementation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil Supplementation</intervention_name>
    <arm_group_label>Fish Oil Supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flaxseed Oil Supplementation</intervention_name>
    <arm_group_label>Flaxseed Oil Supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo Supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Fasting glucose between 7.0 and 14.0 mmol/L, and HbA1c&lt;9%;

          2. Male, 40-70 years; female, postmenopausal to 70 years;

          3. Agree to participant in the trial.

        Exclusion Criteria:

          1. Deny to sign the informed consent;

          2. type 1 diabetes;

          3. Family history of hypertriglyceridemia or fasting triglyceride&gt;4.56 mmol/L;

          4. Have severe liver disease, kidney disease or cancer;

          5. Participating in the other clinical trial within 30 days;

          6. Other diseases or conditions, for which the doctor of the patients do not agree his
             or her participating.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Duo Li, Ph.D.</last_name>
    <phone>86+571 88982024</phone>
    <email>duoli@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gansu Second People's Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Fang, Ph.D</last_name>
      <email>fangling9999@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310058</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Duo Li, Ph.D.</last_name>
      <phone>+86 571 88982024</phone>
      <email>duoli@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Duo Li, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zheng JS, Huang T, Yang J, Fu YQ, Li D. Marine N-3 polyunsaturated fatty acids are inversely associated with risk of type 2 diabetes in Asians: a systematic review and meta-analysis. PLoS One. 2012;7(9):e44525. doi: 10.1371/journal.pone.0044525. Epub 2012 Sep 11. Review.</citation>
    <PMID>22984522</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 27, 2013</lastchanged_date>
  <firstreceived_date>May 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Duo li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>randomized controlled trial</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
